Cibisatamab (RO6958688), the most extensively studied bispecific antibody in CRC, targets CEA on colorectal tumor cells and CD3 on T cells, promoting increased T-cell infiltration, activation, and PD-1/PD-L1 upregulation (255). Here, CD274 is linked to colorectal carcinoma.